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Abstract
Background: Ultrasound-guided diagnostic breast biopsy technology represents the current standard of care for
the evaluation of indeterminate and suspicious lesions seen on diagnostic breast ultrasound. Yet, there remains
much debate as to which particular method of ultrasound-guided diagnostic breast biopsy provides the most
accurate and optimal diagnostic information. The aim of the current study was to compare and contrast the 8-
gauge vacuum-assisted biopsy approach and the spring-loaded 14-gauge core biopsy approach.
Methods: A retrospective analysis was done of all ultrasound-guided diagnostic breast biopsy procedures
performed by either the 8-gauge vacuum-assisted biopsy approach or the spring-loaded 14-gauge core biopsy
approach by a single surgeon from July 2001 through June 2009.
Results: Among 1443 ultrasound-guided diagnostic breast biopsy procedures performed, 724 (50.2%) were by the
8-gauge vacuum-assisted biopsy technique and 719 (49.8%) were by the spring-loaded 14-gauge core biopsy
technique. The total number of false negative cases (i.e., benign findings instead of invasive breast carcinoma) was
significantly greater (P = 0.008) in the spring-loaded 14-gauge core biopsy group (8/681, 1.2%) as compared to in
the 8-gauge vacuum-assisted biopsy group (0/652, 0%), with an overall false negative rate of 2.1% (8/386) for the
spring-loaded 14-gauge core biopsy group as compared to 0% (0/148) for the 8-gauge vacuum-assisted biopsy
group. Significantly more (P < 0.001) patients in the spring-loaded 14-gauge core biopsy group (81/719, 11.3%)
than in the 8-gauge vacuum-assisted biopsy group (18/724, 2.5%) were recommended for further diagnostic
surgical removal of additional tissue from the same anatomical site of the affected breast in an immediate fashion
for indeterminate/inconclusive findings seen on the original ultrasound-guided diagnostic breast biopsy procedure.
Significantly more (P < 0.001) patients in the spring-loaded 14-gauge core biopsy group (54/719, 7.5%) than in the
8-gauge vacuum-assisted biopsy group (9/724, 1.2%) personally requested further diagnostic surgical removal of
additional tissue from the same anatomical site of the affected breast in an immediate fashion for a benign finding
seen on the original ultrasound-guided diagnostic breast biopsy procedure.
Conclusions: In appropriately selected cases, the 8-gauge vacuum-assisted biopsy approach appears to be
advantageous to the spring-loaded 14-gauge core biopsy approach for providing the most accurate and optimal
diagnostic information.
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It is well established among breast health care profes-
sionals that ultrasound-guided diagnostic breast biopsy
technology represents the current recommended stan-
dard of care for accomplishment of the most minimally
invasive evaluation of indeterminate and suspicious
l e s i o n ss e e no nd i a g n o s t i cb r e a s tu l t r a s o u n d[ 1 - 3 ] .
Nevertheless, there remains much debate as to which
particular method of ultrasound-guided diagnostic
breast biopsy provides the most accurate and optimal
diagnostic information [4-10]. In this regard, there
seems to be an increasing trend towards the use of lar-
ger-gauged vacuum-assisted biopsy technology for ultra-
sound-guided diagnostic breast biopsies [4-77],
particularly by the 8-gauge vacuum-assisted biopsy
approach [7,8,19,20,22,27,28,31,35,36,40,41,44-47,49-54,
56-58,60-62,65-68,70,74,75]. The purpose of the current
report is to retrospectively compare and contrast the
results of two ultrasound-guided diagnostic breast
biopsy methodologies, the 8-gauge vacuum-assisted
biopsy approach and the spring-loaded 14-gauge core
biopsy approach, amongst a large series of ultrasound-
guided diagnostic breast biopsy procedures performed
by a single surgeon.
Methods
This retrospective study was approved by the Clinical
Scientific Review Committee and by the Cancer Institu-
tional Review Board of The Arthur G. James Cancer
Hospital and Richard J. Solove Research Institute and
Comprehensive Cancer Center of The Ohio State Uni-
versity Medical Center.
All patients who underwent an ultrasound-guided diag-
nostic breast biopsy by a single surgeon (SPP) using an 8-
gauge vacuum-assisted biopsy device or a spring-loaded
14-gauge core biopsy device from the time period of July
2001 through June 2009 were identified. All of the ultra-
sound-guided diagnostic breast biopsy procedures were
performed at The James Comprehensive Breast Center of
The Arthur G. James Cancer Hospital and Richard J.
Solove Research Institute and Comprehensive Cancer
Center of The Ohio State University Medical Center.
These ultrasound-guided diagnostic breast biopsy proce-
dures were all performed using freehand real-time ultra-
sound guidance with high-resolution linear array
transducers, as previously described [8,40]. The 8-gauge
vacuum-assisted biopsies were performed using the 8-
gauge Mammotome
® breast biopsy system (Devicor Medi-
cal Products, Inc., Cincinnati, Ohio). The spring-loaded
14-gauge core biopsies were performed using either the
Achieve
® spring-loaded 14-gauge core biopsy device (Car-
dinal Health, Inc., McGraw Park, Illinois) or the Bard
®
MaxCore™ spring-loaded 14-gauge core biopsy device (C.
R. Bard, Inc., Covington, Georgia).
All of the breast lesions undergoing ultrasound-guided
diagnostic breast biopsy were sonographically visible and
were classified according to the American College of
Radiology (ACR) Breast Imaging Reporting and Data
System (BI-RADS) as either BI-RADS category 3, 4, or
5. All BI-RADS category 4 and 5 ultrasound breast
lesions were strongly recommended for ultrasound-
guided diagnostic breast biopsy. For those ultrasound
breast lesions classified as BI-RADS category 4 and 5,
pre-biopsy mammography was obtained when it was
determined appropriate, as based upon patient age and
clinical indications. However, for those ultrasound
breast lesions classified as BI-RADS category 4 and 5,
further pre-biopsy diagnostic breast imaging with mag-
netic resonance imaging was not considered. As a gen-
eral rule, the vast majority of BI-RADS category 3
ultrasound breast lesions seen at The James Compre-
hensive Breast Center were recommended for serial
short-term patient follow-up alone, consisting of repeat
clinical breast examination and repeat diagnostic breast
imaging at an interval of time of 3 to 6 months after the
designation of an ultrasound breast lesion as BI-RADS
category 3. However, ultrasound-guided diagnostic
breast biopsy was performed on BI-RADS category 3
ultrasound breast lesions when the patient expressed
c o n c e r na n dt h ed e s i r ef o rh a v i n gad i a g n o s t i cb r e a s t
biopsy rather than having serial short-term patient fol-
low-up alone.
For the 8-gauge vacuum-assisted biopsy procedures,
local anesthetic, consisting of 1% lidocaine plain (used
for the skin and superficial tissues, and ranging from 5
to 15 mL) and 1% lidocaine containing 1:100,000 mix-
ture of epinephrine (used for the deeper breast tissues
surround the ultrasound lesion, and ranging from 15 to
30 mL), was utilized. For the spring-loaded 14-gauge
core biopsy procedures, local anesthetic, consisting of
only 1% lidocaine plain (ranging from 15 to 30 mL), was
utilized. After local anesthetic was administered, a #11
blade was used to make an approximately 5 mm skin
incision entrance site for the 8-gauge vacuum-assisted
biopsy procedures and an approximately 2 mm skin
incision entrance site for the spring-loaded 14-gauge
core biopsy procedures. Further details with regard to
the specific techniques used during the 8-gauge
vacuum-assisted biopsy procedures have been previously
reported [8,40]. After the completion of core acquisition
and after the removal of ultrasound-guided diagnostic
biopsy device from the breast, a 14-gauge Cormark™
rigid microclip device (Devicor Medical Products, Inc.,
Cincinnati, Ohio) was inserted under ultrasound gui-
dance through the same breast parenchymal track for
placement of a microclip into the area of the ultra-
sound-guided diagnostic biopsy. Placement of a micro-
clip was done selectively for ultrasound-guided
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2001 to 2004, but was generally done more universally
thereafter.
Manual compression to the breast was generally per-
formed for approximately ten minutes after completion
of the ultrasound-guided diagnostic breast biopsy proce-
dure to assure adequate hemostasis to the biopsy site.
The skin incision entrance site was then generally closed
with either adhesive skin closure strips or absorbable
suture. In selected cases, a circumferential compressive
ace wrap was applied to the chest of patients for a post-
procedural duration of approximately 24 hours.
All submitted ultrasound-guided diagnostic breast
biopsy core specimens were processed in the Depart-
ment of Surgical Pathology for permanent histopatholo-
gic evaluation with routine Hematoxylin and Eosin
(H&E) staining. All information with regards to the his-
topathologic diagnosis was obtained from the official
pathology report issued by the Department of Surgical
Pathology.
The histopathologic findings from each of the original
ultrasound-guided diagnostic breast biopsy procedures
were generally first discussed by telephone with the
patients at the soonest availability of those pathology
results. All patients with abnormal histopathologic find-
ings on pathologic evaluation that clinically warranted
surgical intervention were appropriately counseled and
recommended for such management. The demonstra-
tion of a biopsy-proven neoplasm on the original ultra-
sound-guided diagnostic breast biopsy was generally
recommended for immediate therapeutic surgical exci-
sion. The demonstration of an indeterminate or incon-
clusive finding on the original ultrasound-guided
diagnostic breast biopsy was generally recommended for
immediate diagnostic surgical excision. Indeterminate or
inconclusive finding included high risk breast lesions (i.
e., atypical ductal hyperplasia, atypical lobular hyperpla-
sia, or lobular carcinoma in situ) seen on the original
ultrasound-guided diagnostic biopsy, as well as clinical
o rr a d i o g r a p h i cs u s p i c i o ni na n yg i v e nc a s ew h i c hw a s
out of proportion of the of benign findings seen on the
original ultrasound-guided diagnostic breast biopsy (i.e.,
the results of the original ultrasound-guided i a g n o s t i c
biopsy do not seem to explain the original lesion seen
on breast imaging). All patients with benign findings on
histopathologic evaluation were asked to return for
interval breast-related patient follow-up, generally con-
sisting of clinical breast examination and breast imaging
(consisting of ultrasound and/or mammography) at an
initial recommended follow-up time interval of approxi-
mately 6 months after the time of the original ultra-
sound-guided diagnostic breast biopsy procedure. There
was variability in the timing of interval breast-related
patient follow-up for many patients with benign
pathology secondary to patient availability issues and
patient compliance issues. Some patients with benign
pathology remained completely noncompliant, and,
resultantly, had no interval breast-related patient follow-
up, even after multiple attempts to arrange such follow-
up. There was also variability in the performance of
i n t e r v a lf o l l o w - u pb r e a s ti m a g i n g ,p r i m a r i l yb a s e du p o n
patients’ personal preferences for undergoing such inter-
val follow-up breast imaging. Some patients with benign
findings on the original ultrasound-guided diagnostic
breast biopsy procedure themselves requested an
immediate surgical excision procedure.
Finally, if interval follow-up breast imaging showed
abnormal findings for which an interval, repeat diagnos-
tic breast biopsy procedure was recommended or if
patients themselves requested an interval, repeat diag-
nostic breast biopsy procedure despite stable interval
follow-up breast imaging, then an interval, repeat diag-
nostic breast biopsy procedure was performed in a
delayed fashion.
The data collection of all variables was accomplished
by way of retrospective review of The Ohio State Uni-
versity Medical Center’s electronic medical records sys-
tem. Multiple variables, including patient demographics,
lesion variables, procedural variables, histopathology
variables, and interval breast-related patient follow-up
variables, were evaluated. Interval breast-related patient
follow-up was last updated as of March 2011.
The histopathology results from the biopsy core speci-
mens harvested at the time of each original ultrasound-
guided diagnostic breast biopsy procedure were assessed
in comparison to the final histopathologic diagnosis ren-
dered in each case, and including: (1) those instances in
which further therapeutic or diagnostic surgical removal
of additional tissue from the same anatomical site of the
affected breast was done in an immediate fashion after
the original ultrasound-guided diagnostic breast biopsy
procedure; (2) those instances in which patient-
requested surgical removal of additional tissue from the
same anatomical site of the affected breast was done in
an immediate fashion after having benign findings on
the original ultrasound-guided diagnostic breast biopsy
procedure; (3) those instances in which a subsequent,
interval, repeat diagnostic breast biopsy procedure was
later done in a delayed fashion to the same anatomical
site of the affected breast as results of an abnormality
noted on interval follow-up breast imaging at the time
of interval breast-related patient follow-up; and (4)
those instances in which a patient-requested subsequent,
interval, repeat diagnostic breast biopsy procedure was
later done in a delayed fashion at the time of interval
breast-related patient follow-up to the same anatomical
site of the affected breast after previously having benign
findings on the original ultrasound-guided diagnostic
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follow-up breast imaging at the time of interval breast-
related patient follow-up. This assessment process was
done in order to determine the misestimation of any
given breast finding, the overall number of false negative
findings, and the overall false negative rate. The deter-
mination of the misestimation of any given breast find-
ing, as it pertained to benign breast findings, high risk
breast lesions, ductal carcinoma in situ (DCIS), DCIS
with microinvasion, and invasive carcinoma, was made
for the original ultrasound-guided diagnostic breast
biopsy procedure findings as a direct comparison to the
final histopathologic diagnosis for all cases in which
subsequent therapeutic or diagnostic removal of addi-
tional tissue from the same anatomical site of the
affected breast was performed in an immediate fashion.
The determination of the overall number of false nega-
tive results was made from the entire population of each
group for all patients who returned for some form of
interval breast-related patient follow-up by comparing
the original ultrasound-guided diagnostic breast biopsy
procedure results to that of the final determination of
the status of the affected breast, as based upon those
instances in which subsequent removal of additional tis-
sue from the same anatomical site of the affected breast
was performed in both an immediate fashion and a
delayed fashion, as well as based upon final determina-
tion of the status of the affected breast of all other cases
in each group not undergoing subsequent removal of
additional tissue from the affected breast but who
returned for some form of interval breast-related patient
follow-up. A false negative finding was specifically
defined as any instance in which an ultrasound lesion,
initially shown to be benign at the time of the original
ultrasound-guided diagnostic breast biopsy procedure,
was subsequently shown to be a carcinoma (i.e., invasive
carcinoma or DCIS) on any further subsequent removal
(in an immediate fashion or in a delayed fashion) of
additional tissue from the same anatomical site of the
affected breast. Additionally, the false negative rate for
the identification of a carcinoma (i.e., invasive carcinoma
or DCIS) was calculated from the equation of the num-
ber of the false negative results divided by the sum of
the number of the true positive results and the number
of the false negative results.
T h es o f t w a r ep r o g r a mI B MS P S S
® 19 for Windows
®
(SPSS, Inc., Chicago, Illinois) was used for all statistical
analyses. For univariate comparisons of categorical vari-
ables, either Pearson chi-square test or Fisher exact test
was utilized. Continuous variables were expressed as
median (range) or mean (± standard deviation) or both,
when appropriate. For univariate comparisons of contin-
uous variables, one-way analysis of variance (ANOVA)
was utilized. All univariate P-values that were
determined to be 0.05 or less were considered to be sig-
nificant. All reported P-values were two-sided.
Results
Patient demographics and characteristics of the original
breast lesions are shown in Table 1 for all patients under-
going an ultrasound-guided diagnostic breast biopsy pro-
cedure. Of the 1443 ultrasound-guided diagnostic breast
biopsy procedures performed, 724 (50.2%) were performed
by the 8-gauge vacuum-assisted biopsy technique and 719
(49.8%) were performed by the spring-loaded 14-gauge
core biopsy technique. Patients undergoing an 8-gauge
vacuum-assisted biopsy had a predilection toward having
smaller-sized (median 1.10 cm, range 0.28-5.53), nonpalp-
able lesions that were more frequently classified as either
BI-RADS category 4 (607/724, 83.8%) or BI-RADS cate-
gory 3 (78/724, 10.8%). Whereas, patients undergoing a
s p r i n g - l o a d e d1 4 - g a u g ec o r eb i o p s yh a dap r e d i l e c t i o n
toward having larger-sized (median 2.00 cm, range 0.42-
9.08), palpable lesions that were more frequently classified
as either BI-RADS category 4 (523/719, 72.4%) or BI-
RADS category 5 (177/719, 24.6%).
Procedural variables are shown in Table 2 for all
patients undergoing an ultrasound-guided diagnostic
breast biopsy procedure. Although, at first glance, the
median number of core removed at the time of the
ultrasound-guided diagnostic breast biopsy appeared to
b et h es a m ef o rt h e8 - g a u g ev a c u u m - a s s i s t e db i o p s y
group (6 cores, range 1 to 38) as compared to the
s p r i n g - l o a d e d1 4 - g a u g ec o r eb i o p s yg r o u p( 6c o r e s ,
range 2 to 15), the mean number of core removed was
determined to actually be significantly greater (P <
0.001) for the 8-gauge vacuum-assisted biopsy group
(7.6 ± 5.1) as compared to the spring-loaded 14-gauge
core biopsy group (6.0 ± 2.1). However, as is shown in
Table 2, this finding of the statistical analysis for the
number of cores removed at the time of the ultrasound-
guided diagnostic breast biopsy was purely a reflection
of the impact of the number of cores removed at the
time of those 8-gauge vacuum-assisted diagnostic biopsy
procedures that were also done with the intention to
attempt 8-gauge vacuum-assisted excision of any given
benign breast lesion (median = 8, range 1 to 38; mean =
9.3 ± 5.9, N = 354). This was further exemplified by the
fact that when one looked solely at those individuals
with a final diagnosis of breast cancer, the median and
mean number of cores removed at the time of the ultra-
sound-guided diagnostic breast biopsy appeared to be
similar to or to even have a near-opposite trend (i.e., a
borderline, but non-significant P-value of 0.087) for the
8-gauge vacuum-assisted biopsy group (median = 4,
range 2 to 22; mean = 5.5 ± 3.6, N = 148) as compared
t ot h es p r i n g - l o a d e d1 4 - g a u g ec o r eb i o p s yg r o u p( m e d -
ian = 6, range 2 to 15; mean = 6.0 ±2.2, N = 386).
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the breast biopsy core specimens harvested at the time
of each original ultrasound-guided diagnostic breast
biopsy procedure for all cases are shown in Table 3.
Post-procedural complications are shown in Table 4
for all patients undergoing an ultrasound-guided diag-
nostic breast biopsy procedure. Both the overall number
of post-procedural complications and the individual type
of post-procedural complications were not significantly
different (P = 0.810 and P = 0.922, respectively) for the
8-gauge vacuum-assisted biopsy group versus the
spring-loaded 14-gauge core biopsy group. For neither
the 8-gauge vacuum-assisted biopsy group nor the
spring-loaded 14-gauge core biopsy group was there the
need of subsequent intraoperative surgical management
of any resultant post-procedural complication. Interest-
ingly, for the entire group of 1443 patients undergoing
an ultrasound-guided diagnostic breast biopsy proce-
dure, patients with a diagnosis of carcinoma on the
original ultrasound-guided diagnostic breast biopsy pro-
cedure were more likely (P < 0.001) to have a post-pro-
cedural bleeding complication (93/525, 17.7%) than were
patients without a diagnosis of carcinoma on the origi-
nal ultrasound-guided diagnostic breast biopsy proce-
dure (82/918, 8.9%). Also, interestingly, for the entire
group of 525 with a diagnosis of carcinoma on the origi-
nal ultrasound-guided diagnostic breast biopsy proce-
dure, there was no significant difference (P = 0.284) in
the overall frequency of occurrence of a post-procedural
bleeding complication for the 8-gauge vacuum-assisted
biopsy group (22/148, 14.9%) as compared to for the
spring-loaded 14-gauge core biopsy group (71/377,
18.8%). Nevertheless, if one looked at the occurrence of
a post-procedural bleeding complication separately for
the 8-gauge vacuum-assisted biopsy group and for the
s p r i n g - l o a d e d1 4 - g a u g ec o r eb i o p s yg r o u pa saf u n c t i o n
of having a diagnosis of carcinoma made at the time of
the original ultrasound-guided diagnostic breast biopsy
Table 1 Patient demographics and characteristics of the original breast lesions in all cases of ultrasound-guided
diagnostic breast biopsy (8-gauge vacuum-assisted biopsy or spring-loaded 14-gauge core biopsy)
8-gauge 14-gauge All cases P-value
Total number of cases 724 719 1443 —————————
Age (median, years) 50 (18-87) 49 (18-96) 49 (18-96) 0.498
Gender 0.823
Female 713 (98.5%) 710 (98.7%) 1423 (98.6%)
Male 11 (1.5%) 9 (1.3%) 20 (1.4%)
Breast 0.599
Right 347 (47.9%) 355 (49.4%) 702 (48.6%)
Left 377 (52.1%) 364 (50.6%) 741 (51.4%)
Palpable tumor <0.001
Yes 288 (39.8%) 561 (78.0%) 849 (58.8%)
No 436 (60.2%) 158 (22.0%) 594 (41.2%)
Lesion location 0.201
UOQ 364 (50.3%) 402 (55.9%) 766 (53.1%)
UIQ 155 (21.4%) 124 (17.2%) 279 (19.3%)
LOQ 115 (15.9%) 105 (14.6%) 220 (15.2%)
LIQ 58 (8.0%) 54 (7.5%) 112 (7.8%)
Subareolar 32 (4.4%) 34 (4.7%) 66 (4.6%)
BI-RADS classification on ultrasound <0.001
Category 3 78 (10.8%) 19 (2.6%) 97 (6.7%)
Category 4 607 (83.8%) 523 (72.7%) 1130 (78.3%)
Category 5 39 (5.4%) 177 (24.6%) 216 (15.0%)
Lesion size on ultrasound (median, cm) 1.10 (0.28-5.53) 2.00 (0.42-9.08) 1.50 (0.28-9.08) <0.001
UOQ, upper outer quadrant; LOQ, lower outer quadrant; UIQ, upper inner quadrant; LIQ, lower inner quadrant; BI-RADS, breast imaging reporting and data
system
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loaded 14-gauge core biopsy procedure were more likely
(P < 0.001) to have a post-procedural bleeding compli-
cation with a diagnosis of carcinoma on the original
ultrasound-guided diagnostic breast biopsy procedure
(71/377, 18.8%) than without a diagnosis of carcinoma
on the original ultrasound-guided diagnostic breast
biopsy procedure (18/342, 5.3%), while patients under-
going an 8-gauge vacuum-assisted biopsy procedure
were not more likely (P = 0.208) to have a post-proce-
dural bleeding complication with a diagnosis of carci-
noma on the original ultrasound-guided diagnostic
breast biopsy procedure (22/148, 14.9%) than without a
diagnosis of carcinoma on the original ultrasound-
guided diagnostic breast biopsy procedure (64/576,
11.1%).
The further therapeutic or diagnostic surgical removal
of additional tissue from the same anatomical site of the
affected breast and patient-requested surgical removal of
additional tissue from the same anatomical site of the
affected breast done in an immediate fashion after the
original ultrasound-guided diagnostic breast biopsy pro-
cedure is shown in Table 5. Overall, for all the ultra-
sound-guided diagnostic breast biopsy procedures
performed, further diagnostic or therapeutic removal of
additional tissue from the same anatomical site of the
affected breast was recommended more frequently (P <
0.001) in the group undergoing a spring-loaded 14-
gauge core biopsy procedure (515/719, 71.6%) as
Table 2 Procedural variables for all cases of ultrasound-guided diagnostic breast biopsy (8-gauge vacuum-assisted
biopsy or spring-loaded 14-gauge core biopsy)
8-gauge 14-gauge All cases P-value
Total number of cases 724 719 1443 —————————
Number of cores (all procedures) <0.001
Median (range) 6.0 (1-38) 6.0 (2-15) 6.0 (1-38)
Mean (±SD) 7.6 (±5.1) 6.0 (±2.1) 6.8 (±4.0)
Number of cores (with final pathology as carcinoma) 0.087
Median (range) 4.0 (2-22) 6.0 (2-15) 5.0 (2-22)
Mean (±SD) 5.5 (±3.6) 6.0 (±2.2) 5.9 (±2.6)
Number of cores (with final pathology as benign)
# <0.001
Median (range) 7.0 (1-38) 6.0 (2-14) 6.0 (1-38)
Mean (±SD) 8.2 (±5.4) 6.0 (±2..0) 7.4 (±4.6)
Placement of marking microclip* <0.001
Yes 714 (98.6%) 428 (59.5%) 1142 (79.1%)
No 10 (1.4%) 291 (40.5%) 301 (20.9%)
# For those 8-gauge vacuum-assisted diagnostic biopsies that were done with the intention to attempt 8-gauge vacuum-assisted excision of any given benign
breast lesions (n = 354), the median number of cores was 8 (range, 1 to 38) and the mean number of cores was 9.3 (± 5.9).
* Microclip marking was done selectively for ultrasound-guided diagnostic breast biopsy procedures done during the time period from 2001 to 2004, but was
generally done more universally in all cases thereafter.
Table 3 Histopathology from the breast biopsy core
specimens harvested at the time of the original
ultrasound-guided diagnostic breast biopsy procedure
8-gauge 14-
gauge
All cases
Total number of cases 724 719 1443
Carcinomas
# 148
(20.4%)
377
(52.4%)
525
(36.4%)
High risk breast lesions
# 15 (2.1%) 6 (0.8%) 21 (1.5%)
Fibroadenomas 239
(33.0%)
147
(20.4%)
386
(26.7%)
Benign breast changes/conditions
† 261
(36.0%)
145
(20.2%)
406
(28.1%)
Intraductal papillomas 42 (5.8%) 6 (0.8%) 48 (3.3%)
Indeterminate fibroepithelial breast
lesions
0 (0%) 8 (1.1%) 8 (0.6%)
Benign phyllodes tumors 1 (0.1%) 1 (0.1%) 2 (0.1%)
Malignant phyllodes tumors 0 (0%) 0 (0%) 0 (0%)
Lymphomas/leukemias 4 (0.6%) 7 (1.0%) 11 (0.8%)
Benign lymphoid tissue 13 (1.8%) 21 (2.9%) 34 (2.4%)
Desmoids/fibromatosis 1 (0.1%) 1 (0.1%) 2 (0.1%)
# carcinomas included invasive carcinoma and ductal carcinoma in situ (DCIS).
* high risk breast lesions included atypical ductal hyperplasia, atypical lobular
hyperplasia, and lobular carcinoma in situ.
† benign breast changes/conditions included all of the following
histopathologic terminologies issued in official pathology report from
Department of Surgical Pathology: fibrocystic breast changes, ductal epithelial
hyperplasia, sclerosing adenosis, stromal fibrosis, cyst-formation, ductal
ectasia, fibrous mastopathy, lymphocytic mastopathy, diabetic mastopathy,
columnar cell changes, fat necrosis, hemorrhage, scar-formation,
gynecomastia, adenosis tumor, lactating adenoma, hamartoma, lipoma,
myofibroblastoma, amyloidosis, benign granular cell tumor, epidermal
inclusion cyst, or benign breast tissue with no pathologic changes.
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assisted biopsy procedure (180/724, 24.9%). Most nota-
bly, this was a direct consequence of the fact that 379/
719 (52.7%) of the spring-loaded 14-gauge core biopsy
procedures yielded a biopsy-proven neoplasm that were
recommended for immediate therapeutic surgical exci-
sion while only 153/724 (21.1%) of the 8-gauge vacuum-
assisted biopsy procedures yielded a biopsy-proven
Table 4 Post-procedural complications for all cases of ultrasound-guided diagnostic breast biopsy (8-gauge vacuum-
assisted biopsy or spring-loaded 14-gauge core biopsy)
8-gauge 14-gauge All cases P-value
Post-procedural complication 0.810
Yes 87 (12.0%) 90 (12.5%) 177 (12.3%)
No 637 (88.0%) 629 (87.5%) 1266 (87.7%)
Type of post-procedural complication 0.922
Mild hematoma/skin ecchymosis 70 (9.7%) 69 (9.6%) 139 (9.6%)
Moderate hematoma/skin ecchymosis 16 (2.2%) 20 (2.8%) 36 (2.5%)
Severe hematoma/skin ecchymosis 0 (0%) 0 (0%) 0 (0%)
Infectious complication 1 (0.1%) 1 (0.1%) 2 (0.1%)
Table 5 Further therapeutic or diagnostic surgical removal of additional tissue from the same anatomical site of the
affected breast and patient-requested surgical removal of additional tissue from the same anatomical site of the
affected breast, done in an immediate fashion, after the original ultrasound-guided diagnostic breast biopsy
procedure
8-
gauge
14-
gauge
All
cases
P-value
All cases in which there was a recommendation for further therapeutic or diagnostic surgical
removal of additional tissue from the affected breast, or the patient personally requested surgical
removal of additional tissue from the affected breast in an immediate fashion
180
(24.9%)
515
(71.6%)
695
(48.2%)
<0.001
All cases in which the previous recommendation for further therapeutic or diagnostic surgical
removal of additional tissue from the affected breast was not subsequently undertaken
9
(5.0%)
44
(8.5%)
53
(7.6%)
0.123
All cases in which there was a recommendation for further therapeutic surgical removal of additional
tissue from the affected breast in an immediate fashion for a biopsy-proven neoplasm
153
(21.1%)
379
(52.7%)
532
(36.9%)
<0.001
All cases in which the previous recommendation for further therapeutic surgical removal of
additional tissue from the affected breast for a biopsy-proven neoplasm was not subsequently
undertaken
4
(2.6%)
41
(10.8%)
45
(8.5%)
0.002
Reason why previous recommendation for further therapeutic surgical removal of additional tissue
from the affected breast for a biopsy-proven neoplasm was not subsequently undertaken
———————
Co-existing distant metastatic disease 2
(50.0%)
23
(56.1%)
25
(55.6%)
———————
Co-morbid conditions 1
(25.0%)
13
(31.7%)
14
(31.1%)
———————
Patient elected to pursue treatment elsewhere 1
(25.0%)
5
(12.2%)
6
(13.3%)
———————
All cases in which there was a recommendation for further diagnostic surgical removal of additional
tissue from the affected breast in an immediate fashion for an indeterminate/inconclusive finding on
the original ultrasound-guided diagnostic breast biopsy
18
(2.5%)
81
(11.3%)
99
(6.9%)
<0.001
All cases in which the previous recommendation for further diagnostic surgical removal of additional
tissue from the affected breast in an immediate fashion for an indeterminate/inconclusive finding on
the original ultrasound-guided diagnostic breast was not subsequently undertaken
5
(27.8%)
3
(3.7%)
8
(8.1%)
0.005
Reason why previous recommendation for further diagnostic surgical removal of additional tissue
from the affected breast for an indeterminate/inconclusive finding on the original ultrasound-guided
diagnostic breast was not subsequently undertaken
———————
Patient preferred observation alone 3
(60.0%)
0 (0%) 3
(37.5%)
———————
Patient elected to pursue treatment elsewhere 2
(40.0%)
3
(100%)
5
(62.5%)
———————
All cases in which the patient personally requested further diagnostic surgical removal of additional
tissue from the affected breast in an immediate fashion after having a benign finding on the original
ultrasound-guided diagnostic breast biopsy
9
(1.2%)
54
(7.5%)
63
(4.4%)
<0.001
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peutic surgical excision (P < 0.001). Nevertheless, signifi-
cantly more (p < 0.001) of the spring-loaded 14-gauge
core biopsy procedures (81/719, 11.3%) showed an inde-
terminate or inconclusive finding that was recom-
mended for immediate diagnostic surgical excision to
the affected breast than did the 8-gauge vacuum-assisted
biopsy procedures (18/724, 2.5%). Similarly, in signifi-
cantly more cases (P < 0.001), patients undergoing a
s p r i n g - l o a d e d1 4 - g a u g ec o r eb i o p s yp r o c e d u r et h a t
showed a biopsy-proven benign breast finding (54/719,
7.5%) requested an immediate diagnostic surgical exci-
sion of that biopsy-proven benign breast finding than
did patients undergoing an 8-gauge vacuum-assisted
biopsy that showed a biopsy-proven benign finding (9/
724, 1.2%). This was possibly a consequence of the fact
that median lesion size of biopsy-proven benign breast
findings in patients requesting immediate diagnostic sur-
gical excision of such biopsy-proven benign breast find-
ings was significantly larger (P < 0.001) in the spring-
loaded 14-gauge core biopsy group (2.60 cm, range
0.57-7.02) than in the 8-gauge vacuum-assisted biopsy
group (0.50 cm, range 0.32-1.20).
An assessment of the accuracy of the original ultra-
sound-guided diagnostic breast biopsy by 8-gauge
vacuum-assisted biopsy technique versus by spring-
loaded 14-gauge core biopsy technique for all cases in
which a subsequent surgical excision of additional tissue
from the same anatomical site of the affected breast was
performed in an immediate fashion is shown in Table 6.
Overall, the histopathologic finding on the initial ultra-
sound-guided diagnostic breast biopsy matched exactly
to the final histopathologic diagnosis on a subsequent
immediate surgical excision of tissue from the same ana-
tomical site of the affected breast more frequently (P <
0.001) for the 8-gauge vacuum-assisted biopsy group
(168/171, 98.2%) than for the spring-loaded 14-gauge
core biopsy group (410/471, 87.0%). Significantly more
(P < 0.001) of the spring-loaded 14-gauge core biopsy
results (37/471, 7.9%) showed a mismatch in the type of
benign diagnosis as compared to the 8-gauge vacuum-
assisted biopsy results (0/171, 0%). Although not statisti-
cally significant (P = 0.199), more misestimations of
benign findings instead of invasive carcinoma were
observed for the spring-loaded 14-gauge core biopsy
group (7/471, 1.5%) than for the 8-gauge vacuum-
assisted biopsy group (0/171, 0%) after a subsequent
surgical excision of additional tissue from the same ana-
tomical site of the affected breast was performed in an
immediate fashion.
Interval breast-related patient follow-up variables are
shown in Table 7. Over 90% of patients in both the 8-
gauge vacuum-assisted biopsy group (N = 652) and the
spring-loaded 14-gauge core biopsy group (N = 681)
had some form of interval breast-related patient fol-
low-up. For all patients in each group who returned
for some form of interval breast-related patient follow-
up, the median duration of the last interval breast-
related patient follow-up was greater than 26 months.
For those patient in each group who had benign biopsy
results on the original ultrasound-guided diagnostic
breast biopsy and who were not recommended for or
requested having a subsequent immediate diagnostic or
therapeutic surgical excision of additional tissue and
who returned for some form of interval breast-related
patient follow-up, the median duration of the last
Table 6 Assessment of accuracy of the initial ultrasound-guided diagnostic breast biopsy by 8-gauge vacuum-assisted
biopsy technique versus spring-loaded 14-gauge core biopsy technique for all cases in which a subsequent surgical
excision of tissue from the same anatomical site of the affected breast was performed in an immediate fashion
8-
gauge
14-
gauge
All
cases
P-value
Cases in which a subsequent surgical excision of tissue from the affected breast was performed in
an immediate fashion
171
(23.6%)
471
(65.5%)
642
(44.5%)
<0.001
Histopathologic findings matched exactly for both the initial ultrasound-guided biopsy and the
subsequent immediate surgical excision
168
(98.2%)
410
(87.0%)
578
(90.0%)
<0.001
Mismatch observed in the type of benign diagnosis 0 (0%) 37
(7.9%)
37
(5.8%)
<0.001
Misestimation of benign findings instead of invasive carcinoma 0 (0%) 7 (1.5%) 7 (1.1%) 0.199
Misestimation of benign findings instead of DCIS with microinvasive 0 (0%) 0 (0%) 0 (0%) ———————
Misestimation of benign findings instead of DCIS 0 (0%) 0 (0%) 0 (0%) ———————
Misestimation of high-risk breast lesions instead of invasive carcinoma 0 (0%) 0 (0%) 0 (0%) ———————
Misestimation of high-risk breast lesions instead of DCIS with microinvasive 0 (0%) 0 (0%) 0 (0%) ———————
Misestimation of high-risk breast lesions instead of DCIS 0 (0%) 1 (0.2%) 1 (0.2%) 1.0
Misestimation of DCIS instead of invasive carcinoma 1 (0.6%) 6 (1.3%) 7 (1.1%) 0.682
Misestimation of DCIS instead of DCIS with microinvasion 2 (1.2%) 0 (0%) 2 (0.3%) 0.071
* high risk breast lesions included atypical ductal hyperplasia, atypical lobular hyperplasia, and lobular carcinoma in situ. DCIS: ductal carcinoma in situ
Povoski et al. World Journal of Surgical Oncology 2011, 9:87
http://www.wjso.com/content/9/1/87
Page 8 of 15interval breast-related patient follow-up was greater
than 24 months.
Subsequent, interval, repeat diagnostic breast biopsy
procedures done in a delayed fashion to the same anato-
mical site of the affected breast after having a benign
finding on the original ultrasound-guided diagnostic
breast biopsy procedure are shown in Table 8. There
was no difference (P = 0.211) in the frequency at which
an interval, repeat diagnostic breast biopsy procedure (i.
e., diagnostic, imaged-guided, minimally-invasive breast
biopsy or diagnostic surgical excision) was done in a
delayed fashion to the affected breast after the original
ultrasound-guided diagnostic breast biopsy procedure
showed benign findings for the group undergoing a
s p r i n g - l o a d e d1 4 - g a u g ec o r eb i o p s yp r o c e d u r e( 1 5 / 7 1 9 ,
2.1%) as compared to the group undergoing an 8-gauge
vacuum-assisted biopsy procedure (9/724, 1.2%). The
reasons for these interval, repeat diagnostic breast
biopsy procedures and the type of these interval, repeat
diagnostic breast biopsy procedures are shown in Table
8. In one single case, a benign breast finding from the
initial ultrasound-guided diagnostic breast biopsy for the
Table 7 Interval breast-related patient follow-up variables
8-gauge 14-gauge All cases P-
value
Did the patient return for any interval breast-related patient follow-up? 0.001
Yes 652
(90.1%)
681
(94.7%)
1333
(92.4%)
No 72 (9.9%) 38 (5.3%) 110 (7.6%)
Median duration to last interval breast-related patient follow-up visit for all patients in each group
(months, range)
26.3 (0.4-
101.5)
32.1 (0.3-
113.2)
28.5 (0.3-
113.2)
<0.001
Median duration to last interval breast-related patient follow-up visit for those patients in each group
who had a benign biopsy result and who were not recommended for or requested having a
subsequent immediate surgical excision (months, range)
24.6 (1.9-
101.5)
24.4 (1.2-
96.9)
24.5 (1.2-
101.5)
0.034
Table 8 Subsequent, interval, repeat diagnostic breast biopsy procedures that were later done in a delayed fashion
from the same anatomical site of the affected breast after having a benign finding on the original ultrasound-guided
diagnostic breast biopsy procedure
8-gauge 14-
gauge
All
cases
P-value
All cases in which the patient underwent an interval, repeat diagnostic breast biopsy procedure
done at a delayed time after having a benign finding on the original ultrasound-guided
diagnostic breast biopsy
9 (1.2%) 15
(2.1%)
24
(1.7%)
0.211
Median time to interval, repeat diagnostic breast biopsy procedure (months, range) 12.4 (4.7-
45.4)
9.8 (2.8-
34.1)
12.0 (2.8-
45.4)
0.373
Reason for interval, repeat diagnostic breast biopsy procedure ———————
Residual BIRADS 4 ultrasound lesion 6
(66.7%)
7
(46.7%)
12
(50.0%)
———————
Residual BIRADS 4 MRI lesion 1
(11.1%)
0 (0%) 1 (4.2%) ———————
Developed new BIRADS 4 mammographic lesion 2
(22.2%)
0 (0%) 2 (8.3%) ———————
Patient’s request 0 (0%) 8
(53.3%)
8
(33.3%)
———————
Type of interval, repeat diagnostic breast biopsy procedure ———————
Surgical excision 3
(33.3%)
7
(46.7%)
10
(41.7%)
———————
Ultrasound-guided 8-gauge vacuum-assisted biopsy 5
(55.5%)
7
(46.7%)
12
(50.0%)
———————
Ultrasound-guided 14-gauge core biopsy 0 (0%) 1 (6.7%) 1 (4.2%) ———————
MRI guided 10-gauge biopsy 1
(11.1%)
0 (0%) 1 (4.2%) ———————
Frequency in which a benign breast finding from the original ultrasound-guided diagnostic
breast biopsy was determined to represent an invasive carcinoma at the time of the interval,
repeat diagnostic breast biopsy procedure done at a delayed time
0/9 (0%) 1/15
(6.7%)
1/24
(4.2%)
1.000
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mined to actually represent an invasive carcinoma at the
time of the interval, repeat diagnostic breast biopsy pro-
cedure done in a delayed fashion.
The final histopathologic diagnosis for all cases, which
included any changes made in the final histopathologic
diagnosis as a result of all instances in which subsequent
diagnostic removal of additional tissue from the same
anatomical site of the affected breast was performed in
an immediate fashion or in a delayed fashion, is shown
in Table 9.
Overall, for those patients who returned for some
form of interval breast-related patient follow-up (N =
1333), the total number of false negative results, as
defined as an initial ultrasound-guided diagnostic breast
biopsy showing benign findings but a subsequent
removal of additional tissue from the same anatomical
site of the affected breast (done in either an immediate
fashion or a delayed fashion) showing breast carcinoma,
was significantly greater (P = 0.008) in the spring-loaded
14-gauge core biopsy group (8/681, 1.2%) as compared
to in the 8-gauge vacuum-assisted biopsy group (0/652,
0%). In all eight cases, this represented a missed invasive
breast carcinoma. This translates into an overall false
negative rate for the identification of an invasive breast
carcinoma of 2.1% (8/386) for the spring-loaded 14-
gauge core biopsy group as compared to 0% (0/148) for
the 8-gauge vacuum-assisted biopsy group. There was
no apparent relationship noted between the size of the
ultrasound lesion originally biopsied by the ultrasound-
guided spring-loaded 14-gauge core biopsy approach to
that of the overall false negative rate, since no difference
(P = 0.786) was demonstrated in the median lesion size
for those eight cases of a false negative result (2.36 cm,
range 0.91-3.00) from the spring-loaded 14-gauge core
biopsy group as compared to the entire spring-loaded
14-gauge core biopsy group (2.00 cm, range 0.42-9.08).
However, as expected, there was a marginal relationship
(P = 0.059) between the BI-RADS classification and the
total number of false negative results in the spring-
loaded 14-gauge core biopsy procedure group for those
individuals who returned for some form of interval
breast-related patient follow-up (N = 681), with 0 false
negative results in 19 patients (0%) who had a BI-RADS
category 3 lesion on their initial ultrasound, versus 3
false negative results in 485 patients (0.6%) who had a
BI-RADS category 4 lesion on their initial ultrasound,
versus 5 false negative results in 177 patients (2.8%)
who had a BI-RADS category 5 lesion on their initial
ultrasound.
For the patients evaluated in this study during the
time period from July 2001 through June 2009, two
patients in the spring-loaded 14-gauge core biopsy pro-
cedure group and three patients in the 8-gauge vacuum-
assisted biopsy procedure group subsequently developed
a breast cancer event in a different anatomical site of
the ipsilateral breast that was geographically separate
from the location of the original ultrasound-guided diag-
nostic breast biopsy procedure. These events occurred at
27 months and 29 months after the original ultrasound-
guided diagnostic breast biopsy for the two spring-
loaded 14-gauge core biopsy patients and occurred at 9
months, 48 months, and 56 months after the original
ultrasound-guided diagnostic breast biopsy for the three
8-gauge vacuum-assisted biopsy patients.
Discussion
When carefully scrutinizing the data from our currently
reported series, several important findings become
apparent with regards to the methodology of ultra-
sound-guided diagnostic breast biopsy. First, and fore-
most, when specifically looking at all of the patients
who underwent some form of interval breast-related
patient follow-up (N = 1333), the total number of false
negative cases (i.e., benign findings instead of invasive
breast carcinoma) was found to be significantly greater
Table 9 Final histopathologic diagnosis, including all
instances in which subsequent diagnostic removal of
tissue from the same anatomical site of the affected
breast was performed in an immediate fashion or in a
delayed fashion
8-gauge 14-
gauge
All cases
Total number of cases 724 719 1443
Carcinomas
# 148
(20.4%)
386
(53.7%)
534
(37.0%)
High risk breast lesions
# 15 (2.1%) 5 (0.7%) 20 (1.4%)
Fibroadenomas 238
(32.9%)
151
(21.0%)
389
(27.0%)
Benign breast changes/conditions
† 261
(36.0%)
138
(19.2%)
399
(27.7%)
Intraductal papillomas 42 (5.8%) 6 (0.8%) 48 (3.3%)
Indeterminate fibroepithelial breast
lesions
0 (0%) 0 (0%) 0 (0%)
Benign phyllodes tumors 2 (0.3%) 4 (0.6%) 6 (0.4%)
Malignant phyllodes tumors 0 (0%) 1 (0.1%) 1 (0.1%)
Lymphomas/leukemias 4 (0.6%) 7 (1.0%) 11 (0.8%)
Benign lymphoid tissue 13 (1.8%) 20 (2.8%) 33 (2.3%)
Desmoids/fibromatosis 1 (0.1%) 1 (0.1%) 2 (0.1%)
# carcinomas included invasive carcinoma and ductal carcinoma in situ.
* high risk breast lesions included atypical ductal hyperplasia, atypical lobular
hyperplasia, and lobular carcinoma in situ.
† benign breast changes/conditions included all of the following
histopathologic terminologies issued in official pathology report from
Department of Surgical Pathology: fibrocystic breast changes, ductal epithelial
hyperplasia, sclerosing adenosis, stromal fibrosis, cyst-formation, ductal
ectasia, fibrous mastopathy, lymphocytic mastopathy, diabetic mastopathy,
columnar cell changes, fat necrosis, hemorrhage, scar-formation,
gynecomastia, adenosis tumor, lactating adenoma, hamartoma, lipoma,
myofibroblastoma, amyloidosis, benign granular cell tumor, epidermal
inclusion cyst, or benign breast tissue with no pathologic changes.
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group (8/681, 1.2%) as compared to in the 8-gauge
vacuum-assisted biopsy group (0/652, 0%). This trans-
lates into an overall false negative rate for the identifica-
tion of an invasive breast carcinoma of 2.1% (8/386) for
the spring-loaded 14-gauge core biopsy group as com-
pared to 0% (0/148) for the 8-gauge vacuum-assisted
biopsy group. Second, significantly more (P < 0.001)
patients in the spring-loaded 14-gauge core biopsy
group (81/719, 11.3%) than in the 8-gauge vacuum-
assisted biopsy group (18/724, 2.5%) were recommended
for further diagnostic surgical removal of additional tis-
sue from the same anatomical site of the affected breast
in an immediate fashion for indeterminate/inconclusive
findings seen on the original ultrasound-guided diagnos-
tic breast biopsy procedure. Third, significantly more (P
< 0.001) patients in the spring-loaded 14-gauge core
biopsy group (54/719, 7.5%) than in the 8-gauge
vacuum-assisted biopsy group (9/724, 1.2%) personally
requested further diagnostic surgical removal of addi-
tional tissue from the same anatomical site of the
affected breast in an immediate fashion for a benign
finding seen on the original ultrasound-guided diagnos-
tic breast biopsy procedure. Collectively, these findings
support the use of 8-gauge vacuum-assisted biopsy tech-
nology over that of spring-loaded 14-gauge core biopsy
technology for ultrasound-guided diagnostic breast
biopsy procedure in appropriately selected cases.
As is shown in Table 10, there is an abundance of stu-
dies in the literature reporting on the false negative rate
for the spring-loaded 14-g a u g ec o r eb i o p s ya p p r o a c h
[4,6,78-95]. However, there is a relative paucity of infor-
mation available in the literature that specifically
addresses the accurate determination of the false nega-
tive rate for the 8-gauge vacuum-assisted biopsy
approach. In our currently reported series, the overall
false negative rate for finding an invasive breast carci-
noma by the spring-loaded 14-gauge core biopsy
approach was 2.1% (8/386). This is highly consistent
with the cumulative results of the false negative rate, as
shown in Table 10, for the spring-loaded 14-gauge core
biopsy approach that have been previously reported by
many other authors [4,6,78-95]. This determination and
comparison is very helpful for validating the skill-set
level of the surgeon in the currently reported series who
performed all of the ultrasound-guided diagnostic breast
biopsies, both by the spring-loaded 14-gauge core biopsy
technique and by the 8-gauge vacuum-assisted biopsy
technique. In this specific regard, the overall false nega-
tive rate for the identification of an invasive breast carci-
noma in the currently reported series by the 8-gauge
vacuum-assisted biopsy approach was 0%. This represent
a series of 724 patients undergoing an 8-gauge vacuum-
assisted biopsy procedures, in which 652 of those
patients underwent some form of interval breast-related
patient follow-up, and which constituted a total of 148
cases in which a breast carcinoma was diagnosed by the
8-gauge vacuum-assisted biopsy approach. To date, this
represents the largest reported series of breast carcino-
mas diagnosed by the 8-gauge vacuum-assisted biopsy
technique and the most comprehensive evaluation of
the efficacy of the 8-gauge vacuum-assisted biopsy
approach.
In the currently reported series, the statistical analysis
demonstrates that there was some degree of inherent
selection bias created by the surgeon regarding the deci-
sion-making process as to whether the 8-gauge vacuum-
assisted biopsy approach or the spring-loaded 14-gauge
core biopsy approach was utilized for performing any
given ultrasound-guided diagnostic breast biopsy proce-
dure. Specifically, there was a predilection toward utiliz-
ing the 8-gauge vacuum-assisted biopsy approach for
smaller-sized ultrasound lesions (i.e., those less than 1.0
cm to 1.5 cm in greatest dimension), nonpalpable
lesions, and/or lesions that were classified as either BI-
RADS category 4 or 3; whereas, there was a predilection
toward utilizing the spring-loaded 14-gauge core biopsy
approach for larger-sized ultrasound lesions (i.e., those
greater than 2.0 cm to 2.5 cm in greatest dimension),
Table 10 Studies specifically reporting on the false
negative rate of identifying breast malignancies based
upon the ultrasound-guided 14-gauge core diagnostic
breast biopsy approach
Citation [reference] False negative rate
Parker 1993 [78] 0% (0/34)
Nguyen 1996 [79] 2.1% (4/187)
Liberman 2000 [80] 3.7% (9/241)
Schoonjans 2001 [81] 1.7% (4/243)
Buchberger 2002 [82] 1.3% (3/234)
Memarsadeghi 2003 [83] 3.1% (5/161)
Philpotts 2003 [4] 2.8% (1/36)
Shah 2003 [84] 3.6% (3/84)
Delle Chiaie 2004 [85] 3.1% (4/128)
Fajardo 2004 [86] 2.6% (2/77)
Pijnappel 2004 [87] 11.8% (8/68)
Cho 2005 [6] 3.1% (4/128)
Crystal 2005 [88] 3.1% (10/323)
Dillon 2005 [89] 1.7% (13/769)
Sauer 2005 [90] 2.3% (14/618)
Vega Bolivar 2005 [91] 3.3% (4/122)
Wu 2006 [92] 2.4% (5/209)
Fan 2008 [93] 1.1% (18/1584)
Schueller 2008 [94] 1.6% (11/709)
Youk 2009 [95] 2.5% (50/1982)
Cumulative results 2.2% (172/7937)
Povoski 2011 2.1% (8/386)
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Page 11 of 15palpable lesions, and/or lesions that were classified as
either BI-RADS category 4 or 5. Hence, this demon-
strates an inherent but understandable selection bias for
utilizing the spring-loaded 14-gauge core biopsy techni-
que for ultrasound lesions which appear to represent
more obvious breast cancers, based upon their larger
size and their more suspicious appearance on diagnostic
breast imaging, and is supported by the findings in the
current reported series in which 52.4% (377/719) of the
ultrasound lesions approached by the spring-loaded 14-
g a u g ec o r eb i o p s yt e c h n i q u ea tt h et i m eo ft h eo r i g i n a l
ultrasound-guided diagnostic breast biopsy procedure
were breast carcinomas while only 20.4% (148/724) of
the ultrasound lesions approached by the 8-gauge
vacuum-assisted biopsy t e c h n i q u ew e r eb r e a s t
carcinomas.
Despite this inherent but understandable selection bias
for utilizing the spring-loaded 14-gauge core biopsy
technique for ultrasound lesions which appear to repre-
sent more obvious breast cancers, there are several less
obvious but still very key points that are worth mention-
ing with regards to appropriate patient selection for
whether the 8-gauge vacuum-assisted biopsy approach
or the spring-loaded 14-gauge core biopsy approach is
utilized for performing any given ultrasound-guided
diagnostic breast biopsy procedure. While these key
points may embody the opinion of the authors of the
currently reported series, they are potentially useful to
all breast health care professionals that utilize ultra-
sound-guided diagnostic breast biopsy technology.
The first less obvious but still key point relates to the
issue of the adequacy of tissue sampling for small, sub-
centimeter, but highly suspicious (i.e., BI-RADS category
4 or 5) ultrasound lesions [8]. There is always an inher-
ent degree of uncertainty that exists within one’sm i n d
when using the spring-loaded 14-gauge core biopsy
technique secondary to concerns about positional over-
shooting or undershooting that may occur with the tis-
sue acquisition chamber when firing the spring-loaded
14-gauge core biopsy device when attempting to target
any such small, subcentimeter ultrasound lesion. In con-
trast, approaching such small, subcentimeter ultrasound
lesions by the 8-gauge vacuum-assisted biopsy technique
allows for more representative and even potentially
complete tissue sampling of any given small, subcenti-
meter region of interest in a more precise and directed
fashion. This line of reasoning was utilized in the cur-
rently reported series in which 39.2% (58/148) of breast
carcinomas diagnosed by the 8-gauge vacuum-assisted
biopsy technique were less than 1 cm in size, while only
4.9% (19/386) of breast carcinomas diagnosed by the
spring-loaded 14-gauge core biopsy technique were less
than 1 cm in size (P < 0.001). Such an approach may be
highly advantageous for helping to potentially minimize
the risks for misestimation of any given breast finding
and for reducing the risks of false negative results for
finding a breast carcinoma at the time of ultrasound-
guided diagnostic breast biopsy.
The second less obvious but still key point relates to
the issue of tissue sampling of larger-sized but vaguely
characterized areas within the breast that may be of
clinical concern and/or radiographic concern. Several
examples of this scenario easily come to mind and
include: (1) attempting to differentiate diabetic mastopa-
thy from that of a breast carcinoma; (2) attempting to
differentiate scar tissue and post-surgical changes within
the breast from that of a breast carcinoma; and (3)
attempting to differentiate severe fibrocystic breast
changes from that specifically of invasive lobular carci-
noma. In these particular situations, a spring-loaded 14-
gauge core biopsy approach to ultrasound-guided diag-
nostic breast biopsy may prove highly difficult due to
the inability for the tissue acquisition chamber of the
s p r i n g - l o a d e d1 4 - g a u g ec o r eb i o p s yd e v i c et oc o r r e c t l y
and completely fire through such breast tissue of
increased breast tissue density that is frequently encoun-
tered in these particular situations. Likewise, in these
particular situations, a spring-loaded 14-gauge core
biopsy approach may create concerns about the cer-
tainty of the degree of representative tissue sampling of
a larger-sized but vaguely characterized area of interest
within the breast. On the other hand, in these particular
situations, an 8-gauge vacuum-assisted biopsy approach
to ultrasound-guided diagnostic breast biopsy would
allow for single-pass, central placement of the device
within such a larger-sized but vaguely characterized area
of interest within the breast, despite the finding of gen-
eralized increased breast tissue density, with subsequent
ease of tissue acquisition of multiple 8-gauge cores in
up to a complete 360 degree rotational array. Resul-
tantly, this would allow for the achievement of large-
volume and highly representative tissue sampling of the
entire larger-sized but vaguely characterized area of
interest within the breast, thus maximizing the accuracy
of tissue diagnosis and reducing the potential risks of
false negative results for correctly identifying a breast
carcinoma.
Conclusions
The 8-gauge vacuum-assisted biopsy approach to ultra-
sound-guided diagnostic breast biopsy appears to be
advantageous to that of the spring-loaded 14-gauge core
biopsy approach for providing the most accurate and
optimal diagnostic information. In appropriately selected
patients, the 8-gauge vacuum-assisted biopsy approach
can: (1) minimize the overall false negative rate for diag-
nosing invasive breast carcinoma; (2) reduce the subse-
quent need for further diagnostic removal of additional
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Page 12 of 15tissue from the affected breast in an immediate fashion
for indeterminate/inconclusive findings; and (3) reduce
patient-requested further diagnostic removal of addi-
tional tissue from the affected breast in an immediate
fashion despite benign finding the original ultrasound-
guided diagnostic breast biopsy procedure. The impor-
tance of appropriate patient selection for either of these
ultrasound-guided diagnostic breast biopsy approaches
can not be underestimated and must be well understood
by those breast health care professionals utilizing ultra-
sound-guided diagnostic breast biopsy technology.
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